immunotherapy

Innate Pharma SA (IPHA) will host a conference call on November 13, 2025, to discuss its Q3 2025 business progress. Key executives will present and answer questions. The call will be webcast live and available for replay on the company website. Innate Pharma focuses on developing immunotherapies, including lacutamab, IPH4502, and monalizumab. Investors will focus on clinical trial updates, cash runway, and competitive advantages. Note the presence of forward-looking statements subject to risks detailed in company filings.

Northwest Biotherapeutics (NWBO) announced the passing of Senior Vice President and General Counsel, Les Goldman. Goldman was a key contributor to NWBO, a biotech firm focused on personalized immune therapies for solid tumor cancers, particularly via its DCVax® platform. NWBO is advancing DCVax®-L for glioblastoma, with UK regulatory review underway. They are also developing DCVax®-Direct for inoperable solid tumors. His responsibilities are being assumed by existing management.

The TROPION-Lung02 and TROPION-Lung04 trials support DATROWAY (datopotamab deruxtecan) combined with immunotherapy as a first-line treatment for advanced NSCLC. TROPION-Lung02 showed a 54.8% objective response rate with DATROWAY and pembrolizumab. Exploratory analyses show promising biomarker associations and the TROPION-Lung04 study found a 57.5% objective response rate when using DATROWAY with rilvegostomig. NeoCOAST-2 data also revealed positive results in the neoadjuvant setting.

Innovent Biologics announced positive Phase 1/2 data for IBI363, a PD-1/IL-2α-bias bispecific antibody, at ASCO 2025. The study showed promising results in immunotherapy-resistant acral and mucosal melanoma (“cold tumors”), demonstrating a 23.3% confirmed objective response rate and 14.8 months median overall survival. A Phase 2 registration trial for IBI363 is underway, offering a potential breakthrough for advanced melanoma treatment.